Article
- The EMBO Journal (2001) 20, 3484 - 3494
- doi:10.1093/emboj/20.13.3484
Rsk2 allosterically activates estrogen receptor
by docking to the hormone-binding domain
David E. Clark1, Celeste E. Poteet-Smith1, Jeffrey A. Smith1,2 and Deborah A. Lannigan1,2
- Center for Cell Signaling University of Virginia, Charlottesville, VA 22908-0577, USA
- Center for PharmaBiologicals, University of Virginia, Charlottesville, VA 22908-0577, USA
Correspondence to:
Deborah A. Lannigan, E-mail: dal5f@virginia.edu
Received 8 November 2000; Accepted 16 May 2001; Revised 4 April 2001
Abstract
We describe a novel mechanism for transcriptional regulation, in which docking of p90 ribosomal S6 kinase 2 (Rsk2) to the hormone-binding domain (HBD) of estrogen receptor
(ER
) induces a conformational change that enhances the transcriptional activation function contained in the HBD. A constitutively active mutant of Rsk2 specifically enhances ER
-mediated transcription by phosphorylation of Ser167 in ER
and by physically associating with residues 326–394 of the ER
HBD. The anti-estrogen 4-hydroxytamoxifen blocks Rsk2-mediated activation of ER
, by inducing a conformation of ER
in which the Rsk2 docking site is masked. Transcriptional activation and docking are specific for ER
and do not occur with the related isoform, ER
. ER
phosphorylation, docking and transcriptional activation are regulated by the Rsk2 N-terminal kinase domain. The allosteric regulation of a target protein, independent of phosphorylation, may be paradigmatic of a general function for protein kinase docking sites.
Keywords:
- allosteric,
- estrogen receptor
, - p90 ribosomal S6 kinase 2,
- transcription



